GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stem Cells Spin SA (WAR:SCS) » Definitions » Total Liabilities

Stem Cells Spin (WAR:SCS) Total Liabilities : zł5.07 Mil (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Stem Cells Spin Total Liabilities?

Stem Cells Spin's Total Liabilities for the quarter that ended in Dec. 2024 was zł5.07 Mil.

Stem Cells Spin's quarterly Total Liabilities declined from Jun. 2024 (zł5.75 Mil) to Sep. 2024 (zł5.60 Mil) and declined from Sep. 2024 (zł5.60 Mil) to Dec. 2024 (zł5.07 Mil).

Stem Cells Spin's annual Total Liabilities declined from Dec. 2022 (zł7.22 Mil) to Dec. 2023 (zł6.18 Mil) and declined from Dec. 2023 (zł6.18 Mil) to Dec. 2024 (zł5.07 Mil).


Stem Cells Spin Total Liabilities Historical Data

The historical data trend for Stem Cells Spin's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stem Cells Spin Total Liabilities Chart

Stem Cells Spin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.33 9.53 7.22 6.18 5.07

Stem Cells Spin Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.18 5.91 5.75 5.60 5.07

Stem Cells Spin Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Stem Cells Spin's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.108+(0.003+4.957
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.07

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=11.981-6.913
=5.07

Stem Cells Spin's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.108+(0.003+4.957
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.07

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=11.981-6.913
=5.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stem Cells Spin Total Liabilities Related Terms

Thank you for viewing the detailed overview of Stem Cells Spin's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Stem Cells Spin Business Description

Traded in Other Exchanges
N/A
Address
Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.